Anti-tumor necrosis factor therapies

Current Opinion in Rheumatology
Peter C Taylor

Abstract

Recently published studies confirm that the long-term use of biologicals targeting tumor necrosis factor-alpha (TNF-alpha) in therapy for rheumatoid arthritis (RA) gives rise to sustained improvement in symptoms and signs of disease provided the anti-TNF agent is efficacious and of low immunogenicity. The current regimens for infliximab 3 or 10 mg/kg infusion in combination with weekly oral methotrexate, or of etanercept 25 mg subcutaneously twice per week, appear to fulfill these criteria. D2E7, a "human" antibody produced by phage display, has also been used for over a year. It has recently emerged that anti-TNF therapy protects joints from structural damage. The 1-year data for infliximab and methotrexate combination therapy suggest that this regimen reduces disability. In early RA, etanercept acts more rapidly than methotrexate to decrease symptoms and retard the progression of erosions. In conclusion, for patients with established and early RA, anti-TNF therapies set a new standard for symptom control and joint protection.

References

Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
Apr 25, 2000·Annual Review of Medicine·R N Maini, P C Taylor
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

❮ Previous
Next ❯

Citations

Sep 5, 2002·Arthritis and Rheumatism·Peter D KentEric L Matteson
Dec 17, 2003·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·P Sarzi-PuttiniG Bianchi-Porro
Dec 17, 2008·Gene Therapy·J A CirelliW V Giannobile
Mar 12, 2005·Southern Medical Journal·Petros Efthimiou, Joseph A Markenson
Oct 10, 2009·Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·Péter CsomorTamás Karosi
Jul 10, 2004·Annals of the Rheumatic Diseases·K L HyrichD P M Symmons
Jul 13, 2004·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Maria G BelvisiMark A Birrell
Jan 5, 2002·Journal of Neuroimmunology·Premkumar Christadoss, Elzbieta Goluszko
Jan 9, 2003·Expert Opinion on Investigational Drugs·David J Hele, Maria G Belvisi
Feb 22, 2012·Immunology Letters·Tamás Németh, Attila Mócsai
Jun 19, 2007·The Journal of Surgical Research·C Keith OzakiScott A Berceli
Aug 16, 2003·British Journal of Clinical Pharmacology·C BroadhurstJ K Dhesi
Apr 18, 2009·Muscle & Nerve·Dominic B Fee, Edward J Kasarskis
Feb 2, 2008·The Journal of Pharmacy and Pharmacology·Rong LiLei Zhang
Jan 5, 2005·American Journal of Ophthalmology·James A GarrityDavid M Waitzman
Dec 21, 2014·International Immunopharmacology·Liming XuDeshan Li
Jan 24, 2003·Expert Opinion on Therapeutic Targets·Linda Hibbert, James A Johnston
Jul 23, 2004·Expert Opinion on Therapeutic Targets·Maria G BelvisiMark A Birrell
Apr 2, 2003·Expert Opinion on Therapeutic Targets·Benjamin E Rich
Aug 8, 2007·Journal of Vascular Surgery·C Keith Ozaki
Mar 25, 2014·Case Reports in Rheumatology·Yoshio NagayamaKenrin Shi
Dec 25, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·James M K ChanSharon M Wahl
Jan 7, 2005·Journal of Biomolecular Screening·Robert L YauchDouglas O Clary
Nov 25, 2004·Current Opinion in Biotechnology·Peter C TaylorMarc Feldmann
Mar 26, 2003·Cell Death and Differentiation·H WajantP Scheurich
Apr 13, 2004·Arthritis and Rheumatism·Alfonso MartinezBenjamin Fernandez-Gutierrez
Sep 4, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Lena BrånénStefan Jovinge
Jul 31, 2007·Advances in Therapy·Li-Qin TangXiao-Yu Wang
Dec 2, 2009·The Korean Journal of Internal Medicine·Seung Won ChoiSung Do Cho
May 8, 2020·Clinical and Experimental Immunology·J M FletcherC M Smith
Aug 2, 2006·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Christopher P Stowell
Dec 14, 2017·International Journal of Molecular Sciences·Yu Ri WooHyun Jeong Park
Jun 28, 2002·The Annals of Pharmacotherapy·Leonard H Calabrese

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
L B Hughes, L W Moreland
Current Opinion in Allergy and Clinical Immunology
Joel N Kline
© 2021 Meta ULC. All rights reserved